Subjects

Abstract

Background

The aim of this study was to assess expert gastroenterologists’ opinion on treatment for distinct gastroesophageal reflux disease (GERD) profiles characterized by proton pump inhibitor (PPI) unresponsive symptoms.

Methods

Fourteen esophagologists applied the RAND/UCLA Appropriateness Method to hypothetical scenarios with previously demonstrated GERD (positive pH-metry or endoscopy) and persistent symptoms despite double-dose PPI therapy undergoing pH-impedance monitoring on therapy. A priori thresholds included: esophageal acid exposure (EAE) time >6.0%; symptom-reflux association: symptom index >50% and symptom association probability >95%; >80 reflux events; large hiatal hernia: >3 cm. Primary outcomes were appropriateness of four invasive procedures (laparoscopic fundoplication, magnetic sphincter augmentation, transoral incisionless fundoplication, radiofrequency energy delivery) and preference for pharmacologic/behavioral therapy.

Results

Laparoscopic fundoplication was deemed appropriate for elevated EAE, and moderately appropriate for positive symptom-reflux association for regurgitation and a large hiatal hernia with normal EAE. Magnetic sphincter augmentation was deemed moderately appropriate for elevated EAE without a large hiatal hernia. Transoral incisionless fundoplication and radiofrequency energy delivery were not judged appropriate in any scenario. Preference for non-invasive options was as follows: H2RA for elevated EAE, transient lower esophageal sphincter relaxation inhibitors for elevated reflux episodes, and neuromodulation/behavioral therapy for positive symptom-reflux association.

Conclusion

For treatment of PPI unresponsive symptoms in proven GERD, expert esophagologists recommend invasive therapy only in the presence of abnormal reflux burden, with or without hiatal hernia, or regurgitation with positive symptom-reflux association and a large hiatus hernia. Non-invasive pharmacologic or behavioral therapies are preferred for all other scenarios.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Baldi F. PPI-Refractory GERD: an intriguing, probably overestimated, phenomenon. Curr Gastroenterol Rep. 2015;17:451.

  2. 2.

    Gyawali CP, Roman S, Bredenoord AJ, Fox M, Keller J, Pandolfino JE, Sifrim D, Tatum R, Yadlapati R, Savarino E, International GCWG. Classification of esophageal motor findings in gastro-esophageal reflux disease: conclusions from an international consensus group. Neurogastroenterol Motil. 2017;29: E pub ahead of print.

  3. 3.

    Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional esophageal disorders. Gastroenterology. 2016; E pub ahead of print.

  4. 4.

    Roman S, Gyawali CP, Savarino E, Yadlapati R, Zerbib F, Wu J, Vela M, Tutuian R, Tatum R, Sifrim D, Keller J, Fox M, Pandolfino JE, Bredenoord AJ, group Gc. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;29:1–15.

  5. 5.

    Yadlapati R, Tye M, Keefer L, Kahrilas PJ, Pandolfino JE. Psychosocial distress and quality of life impairment are associated with symptom severity in PPI non-responders with normal impedance-pH profiles. Am J Gastroenterol. 2017;113:31–38.

  6. 6.

    Hussain ZH, Henderson EE, Maradey-Romerao C, George N, Fass R, Lacy BE. The proton pump inhibitor non-responder: a clinical conundrum. Clin Transl Gastroenterol. 2015;6:e115.

  7. 7.

    Hillman L, Yadlapati R, Whitsett M, Thuluvath AJ, Berendsen MA, Pandolfino JE. Review of antireflux procedures for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30:1–14.

  8. 8.

    Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30:1–15.

  9. 9.

    Fitch K, Aguilar MD, Burnand B, La Calle JR, Lazaro P, van het Loo M, McDonnell J, Vader J, Kahan JP. The RAND/UCLA Appropriateness Method User’s Manual. RAND Corporation: Los Angeles, CA, 2001.

  10. 10.

    Buckley FP, 3rd, Bell RCW, Freeman K, Doggett S, Heidrick R Favorable results from a prospective evaluation of 200 patients with large hiatal hernias undergoing LINX magnetic sphincter augmentation. Surg Endosc. 2017; E pub ahead of print.

  11. 11.

    Huang X, Chen S, Zhao H, Zeng X, Lian J, Tseng Y, Chen J. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. Surg Endosc. 2017;31:1032–44.

  12. 12.

    Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc. 2017;31:4865–82.

  13. 13.

    Viazis N, Keyoglou A, Kanellopoulos AK, Karamanolis G, Vlachogiannakos J, Triantafyllou K, Ladas SD, Karamanolis DG. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2012;107:1662–7.

  14. 14.

    Yamasaki T, Fass R. Reflux Hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil. 2017;23:495–503.

  15. 15.

    Riehl ME, Pandolfino JE, Palsson OS, Keefer L. Feasibility and acceptability of esophageal-directed hypnotherapy for functional heartburn. Dis Esophagus. 2016;29:490–6.

  16. 16.

    Pauwels A, Boeckstaens V, Broers C, Iven J, Zhao D, Vanuytsel T, Tack J. A double-blind, placebo-controlled trial with baclofen for the treatment of refractory gastro-esophageal reflux disease. Gastroenterology. 2017;152:S767.

Download references

Author information

Affiliations

  1. Anschutz Medical Campus, University of Colorado, Aurora, CO, USA

    • Rena Yadlapati MD, MSHS
  2. Vanderbilt Medical Center, Nashville, TN, USA

    • Michael F. Vaezi MD, PhD
  3. Mayo Clinic, Scottsdale, AZ, USA

    • Marcelo F. Vela MD
  4. Baylor Health Care System, Dallas, TX, USA

    • Stuart J. Spechler MD
  5. University of North Carolina, Chapel Hill, NC, USA

    • Nicholas J. Shaheen MD, MPH
  6. University of South Florida, Tampa, FL, USA

    • Joel Richter MD
  7. Dartmouth Hitchcock Medical Center, Lebanon, NH, USA

    • Brian E. Lacy MD, PhD
  8. Mayo Clinic, Rochester, MN, USA

    • David Katzka MD
  9. Weill Cornell Medical Center, New York, NY, USA

    • Philip O. Katz MD
  10. Northwestern University, Chicago, IL, USA

    • Peter J. Kahrilas MD
    • , Jenna Craft MPH
    •  & John E. Pandolfino MD, MS
  11. Washington University, St. Louis, MO, USA

    • C. Prakash Gyawali MD
  12. California Pacific Medical Center, San Francisco, CA, USA

    • Lauren Gerson MD, MSc
  13. Metro Health Medical Center, Cleveland, OH, USA

    • Ronnie Fass MD
  14. Medical University of South Carolina, Charleston, SC, USA

    • Donald O. Castell MD
  15. University of Wisconsin, Madison, WI, USA

    • Luke Hillman MD

Authors

  1. Search for Rena Yadlapati MD, MSHS in:

  2. Search for Michael F. Vaezi MD, PhD in:

  3. Search for Marcelo F. Vela MD in:

  4. Search for Stuart J. Spechler MD in:

  5. Search for Nicholas J. Shaheen MD, MPH in:

  6. Search for Joel Richter MD in:

  7. Search for Brian E. Lacy MD, PhD in:

  8. Search for David Katzka MD in:

  9. Search for Philip O. Katz MD in:

  10. Search for Peter J. Kahrilas MD in:

  11. Search for C. Prakash Gyawali MD in:

  12. Search for Lauren Gerson MD, MSc in:

  13. Search for Ronnie Fass MD in:

  14. Search for Donald O. Castell MD in:

  15. Search for Jenna Craft MPH in:

  16. Search for Luke Hillman MD in:

  17. Search for John E. Pandolfino MD, MS in:

Guarantor of the article

Rena Yadlapati

Specific author contributions

Planning and conducting the study (RY, MFV, JC, JEP); Collecting and interpreting data (RY, MFV, MFV, SJS, NJS, JR, BEL, DK, POK, PJK, CPG, LG, RF, DOC, JC, LH, JEP); Drafting the manuscript (RY, MFV, MFV, SJS, NJS, JR, BEL, DK, POK, PJK, CPG, RF, DOC, JC, LH JEP); and Approving final manuscript draft (RY, MFV, MFV, SJS, NJS, JR, BEL, DK, POK, PJK, CPG, RF, DOC, JC, LH, JEP).

Financial support

RY and JEP supported by NIH R01 DK092217 (JEP).

Potential competing interests

MFV, MFV, SJS, JR, DK, POK, PJK, CPG, LG, RF, DOC, JC, LH: None. RY: Consultant for Ironwood. CPG: Research: Medtronic; Consultant: Ironwood, Torax, Quintiles; and Teaching: Medtronic, Sandhill. NJS: Research funding: Boston Scientific, CSA Medical, C2 Therapeutics, CDx Medical, Interpace Diagnostics, and Medtronic. Consultant for Shire and Cook Medical. BEL: Scientific advisory board member for Ironwood, Salix. JEP: Consultant for Crospon, Ironwood, Torax, Astra Zeneca, Takeda, Impleo, Medtronic, and Sandhill.

Corresponding author

Correspondence to Rena Yadlapati MD, MSHS.

Electronic supplementary material

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41395-018-0045-4